ADVICENNE |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.962 EUR | -2.87% |
|
-6.13% | -25.19% |
| 08/04 | Advicenne S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 25/03 | Advicenne: ODD designation in cystinuria | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ADVICENNE | Biopharmaceuticals | -2.87% | -6.13% | -25.19% | -48.71% | -83.35% | 26.5M |  |  | |
Technical Rankings Surperformance
- Stock Market
- Equities
- ALDVI Stock
- Charts Advicenne
- Comparison Chart
